04-Nov-2026 00:10:00
NOVARTINDGeneral news
EVONILE PHARMA : TOTAL DEBT AT ₹800 CR; REVISED FILING ONLY FOR HEADING OMISSION
No change to unaudited results, limited review report or related party disclosures. Total financial indebtedness including short and long term debt at ₹800 Cr as on September 30, 2026; no default. Impact: Neutral (Purely administrative correction of an omitted column heading)
Evonile Pharma Ltd
Open attachment